Atea Pharmaceuticals (AVIR) price target increased by 33.33% to 8.16
Atea Pharmaceuticals (AVIR) has seen its price target increased by 33.33% to $8.16. This adjustment reflects a significant positive outlook on the company's stock valuation.
Atea Pharmaceuticals (AVIR) price target increased by 33.33% to 8.16
This article reports that the price target for Atea Pharmaceuticals (AVIR) has been increased by 33.33% to $8.16. Further details are not available in the provided text.
Vanguard disaggregation leaves Atea stake at 0% (NYSE: AVIR)
The Vanguard Group has filed an amended Schedule 13G/A indicating that its beneficial ownership of Atea Pharmaceuticals (AVIR) common stock is now 0 shares and 0% of the class. This change is due to an internal realignment within Vanguard, where certain subsidiaries will now report their holdings separately in accordance with SEC Release No. 34-39538. The filing clarifies that this disaggregation is an administrative change in reporting structure and does not represent a sale or purchase of Atea's securities.
If You Invested $1,000 in Atea Pharmaceuticals, Inc. (AVIR)
This article analyzes the historical performance of investing $1,000 in Atea Pharmaceuticals, Inc. (AVIR) over various timeframes, comparing its returns to the S&P 500. It highlights that a $1,000 investment made 10 years ago would now be worth $297, underperforming the S&P 500 significantly. The article also provides a detailed overview of Atea Pharmaceuticals, Inc., its focus on oral antiviral therapies for serious viral infections like HCV and HEV, and its clinical development programs for bemnifosbuvir/ruzasvir regimen.
Top 2 Health Care Stocks That May Fall Off A Cliff This Month
As of March 18, 2026, Arcellx Inc. (NASDAQ: ACLX) and Atea Pharmaceuticals Inc. (NASDAQ: AVIR) are identified as overbought health care stocks, potentially signaling a warning to momentum-focused investors. Both companies have seen significant stock gains recently, with their Relative Strength Index (RSI) values well above the overbought threshold of 70, indicating they might be due for a pullback. Gilead Sciences' acquisition of Arcellx and an analyst upgrade for Atea Pharmaceuticals have contributed to their recent surges.
Atea Pharmaceuticals (NASDAQ: AVIR) officer exercises options for 60,000 shares
Atea Pharmaceuticals' officer Andrea Corcoran exercised stock options to acquire 60,000 shares of common stock at $1.24 per share, a routine compensation event. Following this transaction, her direct holdings in Atea common stock increased to 823,576 shares, with no reported same-day sales. This exercise-and-hold pattern is seen as an alignment of compensation with equity.
Atea Pharmaceuticals (NASDAQ:AVIR) Hits New 12-Month High - Here's Why
Shares of Atea Pharmaceuticals (NASDAQ:AVIR) reached a new 52-week high of $6.39 on Tuesday. This rise comes despite mixed analyst sentiment, with a consensus "Hold" rating and a target price of $6.00, and a recent EPS miss. The company, a clinical-stage antiviral developer, has seen increased institutional ownership.
Atea Pharmaceuticals (AVIR) Price Target Raised by Evercore ISI
Evercore ISI Group has maintained its "Outperform" rating on Atea Pharmaceuticals (AVIR) and significantly raised its price target from $6.00 to $10.00. This 66.67% increase reflects the firm's enhanced confidence in the company's future. Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on antiviral therapeutics, with product candidates for COVID-19 and Hepatitis C.
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Atea Pharmaceuticals reported its fourth-quarter and full-year 2025 financial results, highlighting progress in its global Phase 3 program for Hepatitis C Virus (HCV) and the expansion of its antiviral pipeline to include a Hepatitis E Virus (HEV) program. The company expects topline results from its North American HCV trial (C-BEYOND) in mid-2026 and from the C-FORWARD trial outside North America by year-end 2026. Atea also emphasized the potential of its bemnifosbuvir/ruzasvir regimen as a best-in-class HCV treatment and announced the lead HEV candidate, AT-587, is expected to enter clinical development mid-2026.
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2025 Earnings Call Transcript
Atea Pharmaceuticals (NASDAQ:AVIR) held its Q4 2025 earnings call, reporting an EPS miss but highlighting significant clinical progress. The company is advancing its global Phase III program for HCV treatment with bemnifosbuvir and ruzasvir, expecting top-line readouts for both C-BEYOND and C-FORWARD trials this year. Atea also expanded its pipeline into chronic hepatitis E (HEV) with lead candidate AT-587, citing a strong financial position to fund both programs through 2027.
New hepatitis antivirals: inside Atea’s 2026 HCV and HEV trial plans
Atea Pharmaceuticals reported its Q4 and full-year 2025 financial results, including a net loss of $158.3 million and cash/investments of $301.8 million. The company announced the completion of enrollment for its C-BEYOND Phase 3 HCV trial with topline results expected mid-2026, and anticipates C-FORWARD results around year-end 2026. Additionally, Atea plans to initiate clinical development for AT-587, its lead candidate for hepatitis E virus (HEV), in mid-2026.
Earnings call transcript: Atea Pharmaceuticals Q4 2025 sees stock rise despite EPS miss
Atea Pharmaceuticals reported a Q4 2025 EPS of -0.57, missing analyst estimates, but its stock rose 6.43% in aftermarket trading, suggesting investor optimism driven by strong cash reserves and positive clinical trial results for its HCV program. The company expects to extend its cash runway through 2027 and anticipates profitability after launching its HCV treatment, with ongoing clinical trials for both HCV and a new HEV program.
Insights Ahead: Atea Pharmaceuticals's Quarterly Earnings
Atea Pharmaceuticals (NASDAQ: AVIR) is set to release its quarterly earnings report on Thursday, March 5, 2026, with analysts anticipating an EPS of $-0.48. The company's past performance shows that missing EPS estimates has led to share price drops, while shares have risen 63.0% over the last 52 weeks. Investors are optimistic for positive guidance in the upcoming report.
Atea Pharmaceuticals Q4 Earnings Call Highlights
Atea Pharmaceuticals provided progress updates on its Phase 3 Hepatitis C Virus (HCV) program and expanded Hepatitis E Virus (HEV) pipeline during its Q4 2025 earnings call. The company expects top-line readouts for its HCV trials in 2026 and selected AT-587 as its lead HEV candidate, planning first-in-human studies by mid-2026. Atea also reported $301.8 million in cash reserves, projecting a financial runway through 2027, and outlined its commercial strategy for HCV.
Atea Pharmaceuticals (NASDAQ:AVIR) Posts Earnings Results, Misses Expectations By $0.08 EPS
Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly earnings of ($0.57) per share, missing consensus estimates by $0.08. Despite the earnings miss, shares rose by $0.32 to $5.30, nearing its 12-month high. Institutional investors hold a significant portion of the stock, and analysts currently have a "Moderate Buy" rating with a $6.00 price target.
Atea Pharmaceuticals 10-K: $0 Revenue, $(158.3)M Net Loss
Atea Pharmaceuticals reported $0 revenue and a net loss of $(158.3) million for the year ended December 31, 2025, as it has no FDA-approved products. The company has $301.8 million in cash and expects these funds to support operations through 2027 while it advances late-stage clinical programs, including its Phase 3 hepatitis C programs and a planned FDA NDA submission in March 2027. Atea also implemented a 25% workforce reduction in Q1 2025 for efficiency.
Atea Pharmaceuticals (Nasdaq: AVIR) narrows 2025 loss and advances HCV, HEV pipeline
Atea Pharmaceuticals reported a narrower net loss of $158.3 million in 2025, down from $168.4 million in 2024, despite continued investment in its hepatitis portfolio. The company advanced its global Phase 3 HCV program with topline results expected in 2026 and expanded into hepatitis E with lead candidate AT-587, slated for clinical development in mid-2026. Cash reserves stood at $301.8 million at the end of 2025, supporting ongoing R&D efforts.
Insights Ahead: Atea Pharmaceuticals's Quarterly Earnings
Atea Pharmaceuticals (NASDAQ: AVIR) is set to release its quarterly earnings report on Thursday, 2026-03-05. Analysts estimate an EPS of $-0.48. The company's past performance shows a share price drop of 12.57% after missing EPS estimates in the previous quarter, but its shares have risen 63.0% over the last 52 weeks.
Atea Pharmaceuticals (NASDAQ: AVIR) outlines late-stage HCV Phase 3 plans
Atea Pharmaceuticals (NASDAQ: AVIR) is advancing its late-stage Hepatitis C Virus (HCV) program, with topline results for its C-BEYOND Phase 3 trial expected mid-2026 and C-FORWARD trial by year-end 2026, targeting a US NDA submission in March 2027. The company is also developing AT-587 for chronic Hepatitis E Virus (HEV), with a first-in-human Phase 1 study planned for mid-2026. Atea has discontinued its COVID-19 program after its Phase 3 SUNRISE-3 trial did not meet its primary endpoint in 2024.
AVIR Stock News Today | Earnings, Events & Price Alerts
This page provides news and event updates for Atea Pharmaceuticals (AVIR), including financial announcements, clinical trial progress, and conference presentations. Recent news highlights include Atea's participation in major healthcare conferences, progress in its C-BEYOND Phase 3 trial for Hepatitis C, and preclinical results for potential Hepatitis E virus treatments.
Details on Atea Pharma's Q4 and 2025 finances coming March 5
Atea Pharmaceuticals (Nasdaq: AVIR) will host a live conference call and webcast on March 5, 2026, at 4:30 p.m. ET to release its financial results for the fourth quarter and full year ended December 31, 2025, and provide a business update. The event will cover recent progress in its late-stage antiviral clinical programs. Investors can register to participate via phone or webcast, with an archived replay available for at least 90 days.
Atea Pharmaceuticals to Host Fourth Quarter and Full Year
Atea Pharmaceuticals, Inc. announced it will host a conference call and audio webcast on March 5, 2026, at 4:30 p.m. ET to report its financial results for the fourth quarter and full year ended December 31, 2025, and provide a business update. The company, a late-stage clinical biopharmaceutical firm, is focused on developing oral antiviral therapeutics for serious viral diseases. They are advancing their pipeline, including a Phase 3 program for HCV and plans to move AT-587 for HEV into Phase 1 studies.
Atea Pharmaceuticals to Host Fourth Quarter and Full Year
Atea Pharmaceuticals (Nasdaq: AVIR) will host a conference call and audio webcast on Thursday, March 5, 2026, at 4:30 p.m. ET to announce its financial results for the fourth quarter and full year ended December 31, 2025, and to provide a business update. The company is a late-stage clinical biopharmaceutical company focused on developing oral antiviral therapeutics for serious viral diseases, leveraging its proprietary nucleos(t)ide prodrug platform. Interested parties can register for the call or access the webcast via the company's investor relations website.
AVIR SEC Filings - Atea Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Atea Pharmaceuticals (AVIR) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms. It details recent filings like an 8-K summarizing the 2025 Annual Meeting voting outcomes and a Form 4 for a director's equity incentive award. The article also provides real-time updates from EDGAR, AI-powered summaries, and current stock data for AVIR.
AVIR Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Atea Pharmaceuticals, Inc. (AVIR), presenting its income statement, balance sheet, and cash flow data for both annual and quarterly periods. It highlights key financial metrics such as net income, EBITDA, EPS, and cash on hand, noting the company's weak Piotroski F-Score and low earnings quality. The report also addresses common financial questions about the company's profitability, cash runway, and R&D spending, indicating that AVIR is not currently profitable and has a limited cash runway.
Atea Pharmaceuticals (AVIR) to Release Quarterly Earnings on Thursday
Atea Pharmaceuticals (NASDAQ:AVIR) is scheduled to release its Q4 2025 earnings before market open on Thursday, March 5th, with analysts projecting a loss of ($0.49) per share. The company's stock trades within a 52-week range of $2.45–$4.80, with institutional investors holding approximately 86.7% of its shares. Analysts currently have a "Moderate Buy" rating for AVIR, with an average target price of $6.00.
No approved hepatitis E drugs: experimental pill shows powerful lab results
Atea Pharmaceuticals presented preclinical data at CROI 2026 showing their experimental drugs AT-587 and AT-2490 are potent inhibitors of the hepatitis E virus (HEV). AT-587, selected as the lead candidate, demonstrated 30-150 times more potency than existing comparators in vitro, with no observed toxicity. The company plans to initiate a Phase 1 clinical program for AT-587 in mid-2026, aiming to address the significant unmet medical need for HEV treatment, especially in immunocompromised individuals.
Atea Pharmaceuticals Presents Preclinical Results
Atea Pharmaceuticals presented preclinical results at CROI 2026, highlighting two oral nucleotide analogs, AT-587 and AT-2490, as potent inhibitors for Hepatitis E virus (HEV) replication. AT-587 has been selected as the lead candidate for their HEV clinical program, with a Phase 1 clinical trial anticipated to start mid-2026. This development addresses a significant unmet medical need for HEV treatment, especially in immunocompromised patients at high risk of rapid progression to cirrhosis.
Atea Pharmaceuticals (NASDAQ:AVIR) Trading Down 2% - Time to Sell?
Atea Pharmaceuticals (NASDAQ:AVIR) saw its stock price drop by 2% to $4.02, with trading volume slightly below average. The company, a clinical-stage antiviral developer focusing on RNA viruses, reported an earnings per share miss at -$0.53. Despite mixed analyst ratings, the consensus is a "Moderate Buy" with an average price target of $6.00, though analysts forecast a negative EPS for the current fiscal year.
Institutional Investors Are Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Biggest Bettors and Were Rewarded After Last Week's US$56m Market Cap Gain
Institutional investors hold a significant majority, 65%, of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) and benefited most from the company's 21% stock price increase, which added US$56 million to its market capitalization last week. The top six shareholders account for 52% of the business, with FMR LLC, BlackRock, Inc., and BML Capital Management, LLC being the largest institutional holders. Insiders own 15% of the company, including CEO Jean-Pierre Sommadossi with 7.9% of shares, while the general public holds an 11% stake.
JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimens
Atea Pharmaceuticals presented its hepatitis C virus (HCV) strategy at the J.P. Morgan Healthcare Conference, focusing on its bemnifosbuvir/ruzasvir combination for "test-and-treat" models. The company emphasized the regimen's short duration, high potency, and low drug-drug interaction risk, especially for patients using proton pump inhibitors. Topline data for its Phase III C-BEYOND trial are expected mid-2026, with C-FORWARD results by year-end 2026.
JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimens
Atea Pharmaceuticals presented its hepatitis C virus (HCV) strategy at the J.P. Morgan Healthcare Conference, focusing on its bemnifosbuvir/ruzasvir (BEM/RZR) fixed-dose combination. This regimen is designed for expanded "test-and-treat" models, emphasizing its potency, short treatment duration, and low risk of drug-drug interactions. The company announced that enrollment is complete for its C-BEYOND Phase III trial with topline data expected mid-2026, while the C-FORWARD study results are anticipated by the end of 2026.
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Atea Pharmaceuticals (AVIR) and Penumbra (PEN)
This article summarizes recent analyst ratings for three healthcare companies: Boston Scientific (BSX), Atea Pharmaceuticals (AVIR), and Penumbra (PEN). Boston Scientific received a maintained "Buy" rating from Bank of America Securities with a $120 price target, and a "Strong Buy" consensus. Atea Pharmaceuticals also maintained a "Buy" rating from William Blair, holding a "Moderate Buy" consensus. Penumbra was downgraded to "Hold" by Truist Financial and Piper Sandler, with a price target of $374.00, resulting in a "Moderate Buy" consensus.
Atea Pharmaceuticals Highlights Phase 3 HCV Timeline, Unveils New Hepatitis E Candidate AT-587 at JPMorgan Conference
Atea Pharmaceuticals updated on its global Phase 3 program for hepatitis C (HCV) and introduced a new hepatitis E (HEV) antiviral candidate, AT-587, at the JPMorgan Healthcare Conference. The company expects Phase 3 HCV data mid-2026 and plans IND/CTA filings for AT-587 in Q2. Atea also reported a strong financial position with over $300 million in cash, projected to fund operations through early 2028.
Atea Pharmaceuticals to highlight strategic priorities for FY26
Atea Pharmaceuticals (AVIR) plans to present its strategic priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference. The company finished 2025 with $301.8 million in cash and investments, providing a cash runway into 2027. Key upcoming milestones include Phase 3 topline results for its HCV regimen and the initiation of a Phase 1 clinical program for its HEV product candidate AT-587, both anticipated in 2026.
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Atea Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that its CEO and founder, Jean-Pierre Sommadossi, along with other management team members, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. The presentation will be available via live webcast and an archived version will be accessible on the company's website for at least 90 days. Atea Pharmaceuticals focuses on developing oral antiviral therapeutics for serious viral diseases.
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
Atea Pharmaceuticals is set to present its 2026 strategic priorities at the J.P. Morgan Healthcare Conference, focusing on its Phase 3 program for Hepatitis C virus (HCV) treatment and the initiation of a Phase 1 clinical program for Hepatitis E virus (HEV). The company will highlight its potential best-in-class HCV regimen, with topline Phase 3 results expected mid-to-end 2026, and its new HEV product candidate, AT-587, addressing a significant unmet medical need. Atea ended 2025 in a strong financial position, with a cash runway extending through 2027.
New hepatitis C and E treatments move toward key human clinical trials in 2026
Atea Pharmaceuticals (NASDAQ: AVIR) announced its 2026 strategic priorities, including advancing its global Phase 3 program for a hepatitis C virus (HCV) treatment and initiating a Phase 1 study for a hepatitis E virus (HEV) treatment. The company expects topline results for its HCV C-BEYOND trial by mid-2026 and for the C-FORWARD trial by year-end 2026. Atea also highlighted its strong financial position with $301.8 million in cash and investments, providing a runway through 2027.
Atea Pharmaceuticals Advances Phase 3 Trials for HCV Treatment Regimen, Anticipates Significant Milestones in 2026
Atea Pharmaceuticals provided an update on its strategic priorities for 2026, focusing on its global Phase 3 trials for a Hepatitis C virus (HCV) treatment regimen and initiating a Phase 1 clinical program for its Hepatitis E virus (HEV) candidate, AT-587. The company expects topline results from its North American HCV trial (C-BEYOND) by mid-2026 and from the ex-North America trial (C-FORWARD) by year-end 2026. Atea also reported a strong financial position with $301.8 million in cash and investments, providing a cash runway through 2027 to support its clinical developments in antiviral therapies.
Atea Pharmaceuticals Highlights 2026 Strategic Priorities
Atea Pharmaceuticals has outlined its strategic priorities for 2026, focusing on advancing its clinical programs for Hepatitis C virus (HCV) and Hepatitis E virus (HEV). The company ended 2025 with $301.8 million in cash and investments, providing a financial runway through 2027. Key milestones include upcoming Phase 3 readouts for its HCV treatment and the initiation of a Phase 1 program for HEV.
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
Atea Pharmaceuticals is set to outline its strategic priorities for 2026 at the J.P. Morgan Healthcare Conference, focusing on its global Phase 3 program for Hepatitis C virus (HCV) treatment and advancing its Hepatitis E virus (HEV) program. The company expects topline results for its HCV regimen from two Phase 3 trials in mid-2026 and year-end 2026, respectively, and plans to initiate a Phase 1 study for its HEV candidate, AT-587, in mid-2026. Atea reported a strong financial position with $301.8 million in cash and investments at the end of 2025, providing a cash runway through 2027.
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Atea Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that its CEO and management team will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, at 7:30 a.m. PT. A live webcast of the presentation will be available on the company's website. The company specializes in developing oral antiviral therapeutics for serious viral diseases, leveraging a proprietary nucleos(t)ide prodrug platform.
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Atea Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that its CEO and founder, Jean-Pierre Sommadossi, along with other management team members, will present at the 44th Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Thursday, January 15, 2026, at 7:30 a.m. PT in San Francisco, CA, with a live webcast available for those who cannot attend in person. The company specializes in developing oral antiviral therapeutics for serious viral diseases.
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Atea Pharmaceuticals, Inc. announced that its CEO, Jean-Pierre Sommadossi, and other management team members will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. The presentation will be webcast live and archived on the company's website. Atea, a clinical-stage biopharmaceutical company, focuses on developing oral antiviral therapies for serious viral infections.
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Atea Pharmaceuticals, Inc. announced that its CEO, Jean-Pierre Sommadossi, along with other management team members, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. The presentation will be webcast live and archived on the company's website. Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on oral antiviral therapies for serious viral diseases.
Atea Pharmaceuticals: Potential Best-In-Class HCV Cure With Pivotal Readouts In 2026
Atea Pharmaceuticals (AVIR) presents a potentially best-in-class HCV cure candidate, BEM/RZR, currently trading below its cash value with significant upside. This therapy offers the advantages of existing first-line treatments, including a single pill, no drug interactions, short treatment duration, and a high barrier to resistance. Phase 3 trial results are anticipated in 2026, which are expected to drive a strategic transaction for the company.
Is Atea Pharma Moving BEYOND The Virus And FORWARD To Breakthroughs?
Atea Pharmaceuticals (AVIR) is advancing late-stage antiviral programs, most notably its Phase 3 hepatitis C trials for Bemnifosbuvir and Ruzasvir, with topline results expected in 2026. The company is actively expanding its pipeline with new hepatitis E candidates and maintains a strong cash position. These developments position Atea to potentially revolutionize the treatment landscape for viral infections.
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Atea Pharmaceuticals has announced the completion of patient enrollment in its North American C-BEYOND Phase 3 trial for a hepatitis C virus (HCV) treatment. The trial, involving over 880 patients in the US and Canada, evaluates a fixed-dose combination of bemnifosbuvir and ruzasvir. Topline results for C-BEYOND are expected by mid-2026, while enrollment for a similar global trial, C-FORWARD, is anticipated to finish mid-2026 with results by year-end 2026.
Atea Pharmaceuticals Completes Enrollment in C-BEYOND Phase 3 Trial for HCV Treatment, Anticipates Topline Results in Mid-2026 | AVIR Stock News
Atea Pharmaceuticals has completed enrollment for its C-BEYOND Phase 3 trial, involving over 880 treatment-naïve patients in the U.S. and Canada, evaluating a fixed-dose combination of bemnifosbuvir and ruzasvir for HCV treatment. Topline results are expected by mid-2026. Concurrently, the company is advancing the C-FORWARD Phase 3 trial in other regions, with results anticipated by the end of 2026, aiming to provide a best-in-class HCV treatment with short duration and minimal drug interactions.
Atea Pharmaceuticals Completes Enrollment in C-BEYOND Phase 3 Trial for HCV Treatment, Anticipates Topline Results in Mid-2026
Atea Pharmaceuticals has completed enrollment for its C-BEYOND Phase 3 trial, involving over 880 patients in North America to evaluate a novel fixed-dose combination for HCV treatment, with topline results expected by mid-2026. Concurrently, the C-FORWARD trial is advancing outside North America, aiming for enrollment completion and results by year-end 2026. These trials represent the first global Phase 3 head-to-head comparisons of direct-acting antivirals for HCV, striving to offer a best-in-class treatment with short duration and minimal drug interactions.
